Abstract
SummaryAt the European Society for Medical Oncology (ESMO) 2022 annual meeting, several pertinent studies in the field of upper gastrointestinal cancer were presented. The most practice-changing study appeared to be the Destiny-Gastric02 study evaluating trastuzumab–deruxtecan as a second-line treatment option in patients with Her2-positive gastric and gastroesophageal junction cancer. The median overall survival was 12.1 months with a confirmed overall response rate of 41.8%. 55.7% of patients experienced grade ≥ 3 events with nausea, vomiting, and fatigue being the most frequently observed. This study led to the approval of trastuzumab–deruxtecan as second-line therapy in patients with Her2-positive gastric and gastroesophageal junction tumors who have experienced disease progression after first-line trastuzumab-containing therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
